Page last updated: 2024-10-15

n-(deoxyguanosin-8-yl)-2-aminofluorene

Description

N-(deoxyguanosin-8-yl)-2-aminofluorene : Guanosine substituted at the purine 8-position by a (9H-fluoren-2-yl)amino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135562692
CHEBI ID75814
SCHEMBL ID2685407
MeSH IDM0099760

Synonyms (17)

Synonym
aminofluorene-dg
73051-69-1
guanosine, 2'-deoxy-8-(9h-fluoren-2-ylamino)-
2-amino-8-(9h-fluoren-2-ylamino)-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one
8-(9h-fluoren-2-ylamino)-2'-deoxyguanosine
unii-1d7e8eia7k
1d7e8eia7k ,
n-(deoxyguanosin-8-yl)-2-aminofluorene
dg-8-af
dg-c8-af
2'-deoxy-8-(9h-fluoren-2-ylamino)guanosine
CHEBI:75814
SCHEMBL2685407
Q27145563
DTXSID60993823
9-(2-deoxypentofuranosyl)-8-[(9h-fluoren-2-yl)amino]-2-imino-3,9-dihydro-2h-purin-6-ol
2-amino-8-(9h-fluoren-2-ylamino)-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-purin-6-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
guanosinesAny purine ribonucleoside that is a derivative of guanosine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (28.21)18.7374
1990's19 (48.72)18.2507
2000's5 (12.82)29.6817
2010's4 (10.26)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]